SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Barbara Jordan

PatientBarbara Jordan
Date of birth1982-02-21
IdentifiersMRN HR-ML030-SYN; SSN (made up) 000-30-6852
Document date2026-10-26
AuthorEvangeline Moss, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work. [S]

History of Present Illness

Ms. Jordan returns ten weeks after her preventive visit, with a re-baseline brain MRI this morning. She has had no new symptoms and no infection since her first doses. Her mammogram in August was normal, and her HPV test was negative. The heat sensitivity eased as the weather cooled. She finished her course of physical therapy and keeps up her home program and pool exercise; she has had no falls since the near-fall in July. She is teaching a full term and gave two public lectures this month, seated at a lectern. She gets up once a night or less. Dr. Watanabe has reviewed the MRI. Her next infusion, the first full 600 mg dose, is booked in two weeks. [S]

ElementDetail
New symptomsNone
ScreeningMammogram normal; HPV negative
FallsNone; one near-fall in July
WorkFull teaching term and public lectures
Next infusion600 mg in two weeks

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever, infection or weight change
RespiratoryNegativeNo cough
GastrointestinalNegativeNo diarrhea
GenitourinaryNegativeNo burning; nocturia once or less
NeurologicalNegativeNo new numbness, weakness or visual change
PsychiatricNegativeMood steady

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule dailyOne capsule dailyOral route2026-03-02activeS
Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once toleratedOne tablet three times a dayOral route2026-03-16 to 2026-04-20completedS
Baclofen 10 mg oral tablet, one tablet three times a dayOne tablet three times a dayOral route2026-04-20activeS
Mirabegron 25 mg extended-release oral tablet, one tablet dailyOne tablet dailyOral route2026-03-16activeS
Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center300 mg on day 1 and day 15 (given), then 600 mg every 6 monthsIntravenous route2026-05-04activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-26Body height173cmS
2026-10-26Body weight83.2kgS
2026-10-26Body mass index (BMI) [Ratio]27.8kg/m2S
2026-10-26Systolic blood pressure120mm[Hg]S
2026-10-26Diastolic blood pressure76mm[Hg]S
2026-10-26Heart rate72/minS
2026-10-26Respiratory rate16/minS
2026-10-26Body temperature36.6CelS
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-26Leukocytes [#/volume] in Blood by Automated count6.110*3/uL4-11 10*3/uLNormalS
2026-10-26Lymphocytes [#/volume] in Blood by Automated count1.510*3/uL1-4.8 10*3/uLNormalS
2026-10-26Hemoglobin [Mass/volume] in Blood13.5g/dL12-15.5 g/dLNormalS
2026-10-26Platelets [#/volume] in Blood by Automated count25510*3/uL150-400 10*3/uLNormalS
2026-10-26IgG [Mass/volume] in Serum or Plasma1010mg/dL700-1600 mg/dLNormalS
2026-10-26IgM [Mass/volume] in Serum or Plasma72mg/dL40-230 mg/dLNormalS
2026-10-26Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
2026-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M93mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-35 U/LNormalS
2026-10-26Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L10-35 U/LNormalS

Physical Exam

Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 83.2 kg; blood pressure 120/76, pulse 72; temperature 36.6 °C
NeurologicalSpastic gait with a cane; modified Ashworth 1+ in both legs; hip flexor strength 4 out of 5; EDSS 6.0; timed 25-foot walk 11.0 seconds
SkinNo rash or cold sores

Problems

ProblemClinical statusVerificationCodeProvenance
Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spineresolvedconfirmed G35.DS — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts.
Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 2017 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosisactiveconfirmed G35.B1S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts.
Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of fallsactiveconfirmed R26.89S — Synthetic modern coding anchored to her documented cane.
Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residualactiveconfirmed N31.9S — Synthetic; common in multiple sclerosis. No public source describes her bladder.
Vitamin D deficiencyactiveconfirmed E55.9S — Synthetic laboratory finding at intake.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationNew or worsening symptoms (relapse, pseudo-relapse with heat or infection)Every visitCompleted todayNo relapse in eight months
ExaminationDisability: EDSS and timed 25-foot walkEvery visit, and at least every 6 monthsCompleted todayEDSS 6.0; timed 25-foot walk 11.0 seconds
ImagingBrain MRIAt diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadoliniumCompleted todayRe-baseline without gadolinium, five to six months after the first dose: no new or enlarging T2 lesions; next in one year
ImagingSpinal cord MRIAt diagnosis; later only for new spinal symptoms or diagnostic doubtNot indicatedNo new spinal symptoms
LaboratoryBlood count with absolute lymphocytesBefore the first dose, then before each doseCompleted todayWhite cells 6.1, lymphocytes 1.5, hemoglobin 13.5, platelets 255
LaboratoryQuantitative immunoglobulinsBefore the first dose, then before each doseCompleted todayIgG 1010, IgM 72 mg/dL
LaboratoryLiver testsBefore the first dose, then with symptoms and before each doseCompleted todayALT 19, AST 21 U/L; creatinine 0.80 mg/dL
Medication safetyInfusion reactions and infectionsEach infusion, and every visitCompleted todayNo infections; 600 mg dose booked in two weeks
Medication safetyInfluenza and COVID-19 vaccinesEach season, ideally at least 2 weeks before an infusionCompleted todayBoth given today
Medication safetyBreast cancer screening (ocrelizumab label: standard screening)Every two years from 40Up to dateMammogram normal in August
ExaminationSpasticity (modified Ashworth) and baclofen toleranceEvery visitCompleted todayModified Ashworth 1+
ExaminationBladder: urgency, nocturia, urinary infection, and blood pressure on mirabegronEvery visitCompleted todayNocturia once or less; blood pressure 120/76
ReferralFalls, walking aids and physical therapyEvery visitCompleted todayPhysical therapy course completed; no falls
Self-managementFatigue and heat sensitivityEvery visitCompleted todayHeat sensitivity eased with cooler weather
Laboratory25-hydroxyvitamin DAt baseline, 8 to 12 weeks after repletion, then yearlyUp to date34 ng/mL four months ago; recheck at one year
ImagingBone densityOnce for reduced mobility and earlier steroid courses; repeat by riskUp to dateNormal for age at the preventive visit
SurveyDepression screen (PHQ-9)At intake, then every 6 months and with any changeDuePHQ-9 3 four months ago and PHQ-2 0 ten weeks ago; next PHQ-9 at the next review
Self-managementWorkplace accommodationAt intake and with any changeCompleted todayAccommodations working; no change needed
ReferralMultiple sclerosis neurology reviewAt diagnosis, then every 6 months on therapyCompleted todayDr. Watanabe reviewed the MRI and results and agreed with the plan; review in six months

Goal progress:

Immunizations given today: Influenza vaccine, inactivated, this season; COVID-19 vaccine, mRNA, this season [S]

Guideline basis: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); OCREVUS (ocrelizumab) injection, prescribing information (2026); Multiple sclerosis in adults: management (NG220) (2022); Accommodation and Compliance: Multiple Sclerosis (2026); Introduction to the Americans with Disabilities Act (2026); Adult Immunization Schedule by Age (2026); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026); Breast Cancer: Screening (2024)

Follow-up: Ocrelizumab 600 mg in two weeks. Review in three months with the PHQ-9, or the same day for new or worsening symptoms lasting more than 24 hours, fever, or a persistent infection. [S]